Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame	Description
Primary	Percentage of adverse events (AEs)	26 months	Percentage of subjects with adverse events (AEs)
Primary	Percentage of serious adverse events (SAEs)	26 months	Percentage of subjects with serious adverse events (SAEs)
Primary	Percentage of dose limiting toxicities (DLTs)	26 months	Percentage of subjects with dose limiting toxicities (DLTs)
Primary	Percentage of overall response rate (ORR)	26 months	Percentage of overall response rate (ORR) for all participants
Primary	Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1	20 weeks	Assess the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1 based on the safety and response data collected during Phase 1 Escalation
Secondary	Percentage of biologic activity	20 weeks	Percentage of subjects with biological activity determined by tumor biopsies and biomarker data
Secondary	Percentage subjects with detectable RP1	20 weeks	Data gathered from blood, urine, swabs of injection site, dressings, and oral mucosa to determine the shedding and biodistribution of RP1
Secondary	Percentage of complete response (CR)	26 months	Percentage of subjects with a complete response (CR)
Secondary	Median duration of response	26 months	Median duration of response of subjects
Secondary	Median progression-free survival	26 months	Median duration of progression-free survival of subjects
Secondary	Median overall survival	26 months	Median overall survival rate of subjects

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03767348/registered